                         SEQUENCE LISTING

<110>  UCL BUSINESS PLC
 
<120>  Combination Therapeutics

<130>  SMK/LP7440431

<140>  PCT/EP2019/051442
<141>  2019-01-22

<150>  GB 1800994.4
<151>  2018-01-22

<160>  5     

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRAIL-R2-Fx polypeptide mature protein

<400>  1

Ile Thr Gln Gln Asp Leu Ala 
1               5           


<210>  2
<211>  435
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TRAIL-R2-Fc leader peptide

<400>  2

Met Glu Gln Arg Gly Gln Asn Ala Pro Ala Ala Ser Gly Ala Arg Lys 
1               5                   10                  15      


Arg His Gly Pro Gly Pro Arg Glu Ala Arg Gly Ala Arg Pro Gly Pro 
            20                  25                  30          


Arg Val Pro Lys Thr Leu Val Leu Val Val Ala Ala Val Leu Leu Leu 
        35                  40                  45              


Val Ser Ala Glu Ser Ala Leu Ile Thr Gln Gln Asp Leu Ala Pro Gln 
    50                  55                  60                  


Gln Arg Ala Ala Pro Gln Gln Lys Arg Ser Ser Pro Ser Glu Gly Leu 
65                  70                  75                  80  


Cys Pro Pro Gly His His Ile Ser Glu Asp Gly Arg Asp Cys Ile Ser 
                85                  90                  95      


Cys Lys Tyr Gly Gln Asp Tyr Ser Thr His Trp Asn Asp Leu Leu Phe 
            100                 105                 110         


Cys Leu Arg Cys Thr Arg Cys Asp Ser Gly Glu Val Glu Leu Ser Pro 
        115                 120                 125             


Cys Thr Thr Thr Arg Asn Thr Val Cys Gln Cys Glu Glu Gly Thr Phe 
    130                 135                 140                 


Arg Glu Glu Asp Ser Pro Glu Met Cys Arg Lys Cys Arg Thr Gly Cys 
145                 150                 155                 160 


Pro Arg Gly Met Val Lys Val Gly Asp Cys Thr Pro Trp Ser Asp Ile 
                165                 170                 175     


Glu Cys Val His Lys Glu Ser Gly Thr Lys His Ser Gly Glu Val Pro 
            180                 185                 190         


Ala Val Glu Glu Thr Val Thr Ser Ser Pro Gly Thr Pro Ala Ser Cys 
        195                 200                 205             


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 
    210                 215                 220                 


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
225                 230                 235                 240 


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
                245                 250                 255     


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
            260                 265                 270         


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
        275                 280                 285             


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
    290                 295                 300                 


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 
305                 310                 315                 320 


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
                325                 330                 335     


Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 
            340                 345                 350         


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
        355                 360                 365             


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
    370                 375                 380                 


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
385                 390                 395                 400 


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
                405                 410                 415     


His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 
            420                 425                 430         


Pro Gly Lys 
        435 


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hydrophilic residues

<400>  3

Gly Pro Ser Asn Asp Gln Glu Arg Lys 
1               5                   


<210>  4
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  TAL1 target sequence

<400>  4
taccgtttca gatgtca                                                      17


<210>  5
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  TAL2 target sequence

<400>  5
tcgatcttcc tgctgcc                                                      17


